NASDAQ:OPTNOptiNose Stock Price, Forecast & News

OptiNose's stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPTN shares have increased by 2.8% and is now trading at $5.20. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptiNose.

OptiNose is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for OptiNose.

OptiNose Inc (NASDAQ:OPTN) posted its earnings results on Thursday, May, 7th. The company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.03. The firm earned $7.06 million during the quarter, compared to analysts' expectations of $7.56 million. OptiNose had a negative return on equity of 209.89% and a negative net margin of 295.66%. View OptiNose's earnings history.

5 brokers have issued 1 year price targets for OptiNose's shares. Their forecasts range from $17.00 to $25.00. On average, they anticipate OptiNose's stock price to reach $22.20 in the next year. This suggests a possible upside of 326.9% from the stock's current price. View analysts' price targets for OptiNose.

News coverage about OPTN stock has trended somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutOptiNose.

OptiNose saw a drop in short interest in May. As of May 15th, there was short interest totaling 6,060,000 shares, a drop of 5.0% from the April 30th total of 6,380,000 shares. Based on an average daily volume of 326,600 shares, the short-interest ratio is presently 18.6 days. Approximately 25.8% of the shares of the company are sold short. View OptiNose's Current Options Chain.

Some companies that are related to OptiNose include Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Endo International (ENDP), Cue Biopharma (CUE), ImmunoGen (IMGN), Omeros (OMER), Arcturus Therapeutics (ARCT), Gossamer Bio (GOSS), Kura Oncology (KURA), NextCure (NXTC), Kala Pharmaceuticals (KALA), Akero Therapeutics (AKRO), Cara Therapeutics (CARA) and Kadmon (KDMN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Clearside Biomedical (CLSD), Paratek Pharmaceuticals (PRTK), Syndax Pharmaceuticals (SNDX), Coherus Biosciences (CHRS), Ovid Therapeutics (OVID) and Strongbridge Biopharma (SBBP).

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (6.41%), BlackRock Inc. (4.83%), Franklin Resources Inc. (3.13%), Massachusetts Financial Services Co. MA (3.13%), Wasatch Advisors Inc. (2.60%) and Rice Hall James & Associates LLC (2.34%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View institutional ownership trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, Kornitzer Capital Management Inc. KS, Parametric Portfolio Associates LLC, Deutsche Bank AG, Squarepoint Ops LLC, and UBS Group AG. View insider buying and selling activity for OptiNose.

OPTN stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Franklin Resources Inc., Wasatch Advisors Inc., Geode Capital Management LLC, State Street Corp, GSA Capital Partners LLP, Nuveen Asset Management LLC, and JPMorgan Chase & Co.. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil, and Thomas Edward Gibbs. View insider buying and selling activity for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $5.20.

OptiNose has a market capitalization of $238.73 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]